Novo's Amycretin delivers great Phase 2 results

Novo Nordisk's Amycretin produces stellar results in Phase 2 trials -- we dive into Amycretin and other new drugs to see how it compares.

The battle for compounded GLP1 continues

The battle for compounded GLP1s rages on -- powerful organizations with profit incentives continue to push for compounded GLP1s, with consumers caught in the middle.

Government Price negotiations on Ozempic and Wegovy

The government has selected Ozempic and Wegovy for price negotiations -- are we going to see cheaper prices?

Pancreatitis and Gallstones after massive weight loss

We look into pancreatitis and gallstones issues that caused one death and more hospitalizations, caused at least in part by GLP1s

What's the best injection site for GLP1s?

What's the best site for injecting Ozempic, Wegovy, Mounjaro, or Zepbound? We check anecdata, manufacturers, and 3rd parties.

Zepbound coverage for Sleep Apnea gets Agency approval

Center for Medicare and Medicaid declared that Zepbound is covered by insurance for treating Sleep Apnea, given it's effectiveness.

Robert F. Kennedy Jr vs GLP1

RFK Jr.'s appointment and it's effect on GLP1s. Is it truly anti-GLP1? Or a case of tactics?

Research suggesting GLP1 is a brain drug

Why has modern scientific opinion shifted to GLP1 being a brain drug rather than a gut drug? We dive into the critical research paper supporting the shift.

Tirzepatide's benefits extend to Kidney Disease

Tirzepatide (Mounjaro, Zepbound) shows results in weight loss and Hba1c reduction for southerners, critical to kidney disease treatment.

Another Generic Liraglutide launch: Hikma Phamaceuticals

A new player enters the generic GLP1 market - Hikma Pharmaceuticals. As the second generic Liraglutide provider, accessibility of GLP1s has never been better.

HIMS to offer Liraglutide after shortage rule changes

HIMS leans into Liraglutide as a replacement for Semaglutide in the face of shortage rule changes. Is it good enough?

Adlyxin's 2025 Patent expiry

Aldyxin' approaching 2025 patent expiry and what it could mean for new GLP1 drugs.